Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl

PLoS One. 2012;7(12):e51764. doi: 10.1371/journal.pone.0051764. Epub 2012 Dec 11.

Abstract

Background: The dose-dependent toxicities of doxorubicin (DOX) limit its clinical applications, particularly in drug-resistant cancers, such as liver cancer. In this study, we investigated the role of quercetin on the antitumor effects of DOX on liver cancer cells and its ability to provide protection against DOX-mediated liver damage in mice.

Methodology and results: The MTT and Annexin V/PI staining assay demonstrated that quercetin selectively sensitized DOX-induced cytotoxicity against liver cancer cells while protecting normal liver cells. The increase in DOX-mediated apoptosis in hepatoma cells by quercetin was p53-dependent and occurred by downregulating Bcl-xl expression. Z-VAD-fmk (caspase inhibitor), pifithrin-α (p53 inhibitor), or overexpressed Bcl-xl decreased the effects of quercetin on DOX-mediated apoptosis. The combined treatment of quercetin and DOX significantly reduced the growth of liver cancer xenografts in mice. Moreover, quercetin decreased the serum levels of alanine aminotransferase and aspartate aminotransferase that were increased in DOX-treated mice. Quercetin also reversed the DOX-induced pathological changes in mice livers.

Conclusion and significance: These results indicate that quercetin potentiated the antitumor effects of DOX on liver cancer cells while protecting normal liver cells. Therefore, the development of quercetin may be beneficial in a combined treatment with DOX for increased therapeutic efficacy against liver cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Apoptosis / drug effects*
  • Caspase 3 / metabolism
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage*
  • Drug Synergism
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / metabolism
  • Mice
  • Quercetin / administration & dosage*
  • Transplantation, Heterologous
  • Tumor Suppressor Protein p53 / metabolism
  • bcl-X Protein / metabolism

Substances

  • Antineoplastic Agents
  • BCL2L1 protein, human
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • bcl-X Protein
  • Doxorubicin
  • Quercetin
  • Caspase 3

Grants and funding

This work was supported by the National Natural Science Foundation of China (No.: 30400521), the Science Technology Department of Zhejiang Province (No.: 2012R10047 to QD and No.: 2012C33116 to GW) and the Education Department of Zhejiang Province (No.: Y201224108). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.